Literature DB >> 24261626

Involved/uninvolved immunoglobulin ratio identifies monoclonal gammopathy of undetermined significance patients at high risk of progression to multiple myeloma.

Mercedes Espiño1, Silvia Medina, Maria Jesús Blanchard, Luisa M Villar.   

Abstract

Entities:  

Keywords:  Immunoglobulins; heavy/light chain pairs; monoclonal gammopathy of undetermined significance; multiple myeloma; prognostic factors

Mesh：

Substances：

Year:  2013        PMID： 24261626     DOI： 10.1111/bjh.12679

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

1.  Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.

Authors:  Josip Batinić; Zinaida Perić; Dragana Šegulja; James Last; Sanja Prijić; Klara Dubravčić; Lidija Volarić; Dubravka Sertić; Ivo Radman; Sandra Bašić-Kinda; Danica Matišić; Drago Batinić; Boris Labar; Damir Nemet
Journal:  Croat Med J       Date:  2015-06       Impact factor: 1.351

2.  Involved/uninvolved heavy/light chain index can predict progression in transplanted multiple myeloma patients.

Authors:  M Espiño; A Arteche-López; S Medina; C Muñoz-Calleja; M J Blanchard; A Alegre; F J López-Jiménez; L M Villar
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

3.  Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma.

Authors:  Yasuhito Suehara; Hiroyuki Takamatsu; Kota Fukumoto; Manabu Fujisawa; Kentaro Narita; Yoshiaki Usui; Masami Takeuchi; Kelly Endean; Kosei Matsue
Journal:  Cancer Sci       Date:  2017-02       Impact factor: 6.716

4.  Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.

Authors:  Heinz Ludwig; Dejan Milosavljevic; Oscar Berlanga; Niklas Zojer; Wolfgang Hübl; Veronique Fritz; Stephen Harding
Journal:  Am J Hematol       Date:  2016-03       Impact factor: 10.047
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.